Federico Rey

INTRODUCTION: Metabolic dysfunction-associated steatotic liver disease (MASLD) affects over a third of the world population and is increasing at an alarming rate. No FDA-approved pharmacological agents exist to treat MASLD or Metabolic dysfunction-associated steatohepatitis (MASH, advanced MASLD)…